GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » DexCom Inc (WBO:DXCM) » Definitions » Cyclically Adjusted Revenue per Share

DexCom (WBO:DXCM) Cyclically Adjusted Revenue per Share : €5.16 (As of Mar. 2025)


View and export this data going back to 2021. Start your Free Trial

What is DexCom Cyclically Adjusted Revenue per Share?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

DexCom's adjusted revenue per share for the three months ended in Mar. 2025 was €2.352. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is €5.16 for the trailing ten years ended in Mar. 2025.

During the past 12 months, DexCom's average Cyclically Adjusted Revenue Growth Rate was 21.70% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was 26.30% per year. During the past 5 years, the average Cyclically Adjusted Revenue Growth Rate was 29.60% per year. During the past 10 years, the average Cyclically Adjusted Revenue Growth Rate was 34.30% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of DexCom was 39.20% per year. The lowest was 26.30% per year. And the median was 35.30% per year.

As of today (2025-06-30), DexCom's current stock price is €73.57. DexCom's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2025 was €5.16. DexCom's Cyclically Adjusted PS Ratio of today is 14.26.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of DexCom was 71.43. The lowest was 10.55. And the median was 32.76.


DexCom Cyclically Adjusted Revenue per Share Historical Data

The historical data trend for DexCom's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

DexCom Cyclically Adjusted Revenue per Share Chart

DexCom Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only - 2.35 3.22 3.97 5.26

DexCom Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 4.35 4.60 4.63 5.26 5.16

Competitive Comparison of DexCom's Cyclically Adjusted Revenue per Share

For the Medical Devices subindustry, DexCom's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


DexCom's Cyclically Adjusted PS Ratio Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, DexCom's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where DexCom's Cyclically Adjusted PS Ratio falls into.


;
;

DexCom Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, DexCom's adjusted Revenue per Share data for the three months ended in Mar. 2025 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Mar. 2025 (Change)*Current CPI (Mar. 2025)
=2.352/134.9266*134.9266
=2.352

Current CPI (Mar. 2025) = 134.9266.

DexCom Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201506 0.261 100.684 0.350
201509 0.291 100.392 0.391
201512 0.368 99.792 0.498
201603 0.318 100.470 0.427
201606 0.365 101.688 0.484
201609 0.394 101.861 0.522
201612 0.480 101.863 0.636
201703 0.390 102.862 0.512
201706 0.434 103.349 0.567
201709 0.447 104.136 0.579
201712 0.537 104.011 0.697
201803 0.428 105.290 0.548
201806 0.580 106.317 0.736
201809 0.633 106.507 0.802
201812 0.836 105.998 1.064
201903 0.687 107.251 0.864
201906 0.817 108.070 1.020
201909 0.973 108.329 1.212
201912 1.125 108.420 1.400
202003 0.974 108.902 1.207
202006 1.034 108.767 1.283
202009 1.069 109.815 1.313
202012 1.177 109.897 1.445
202103 1.014 111.754 1.224
202106 1.156 114.631 1.361
202109 1.284 115.734 1.497
202112 1.432 117.630 1.643
202203 1.332 121.301 1.482
202206 1.563 125.017 1.687
202209 1.825 125.227 1.966
202212 1.806 125.222 1.946
202303 1.655 127.348 1.753
202306 1.864 128.729 1.954
202309 2.141 129.860 2.225
202312 2.274 129.419 2.371
202403 2.033 131.776 2.082
202406 2.238 132.554 2.278
202409 2.184 133.029 2.215
202412 2.615 133.157 2.650
202503 2.352 134.927 2.352

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.


DexCom  (WBO:DXCM) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

DexCom's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=73.57/5.16
=14.26

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of DexCom was 71.43. The lowest was 10.55. And the median was 32.76.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


DexCom Cyclically Adjusted Revenue per Share Related Terms

Thank you for viewing the detailed overview of DexCom's Cyclically Adjusted Revenue per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


DexCom Business Description

Industry
Address
6340 Sequence Drive, San Diego, CA, USA, 92121
Dexcom designs and commercializes continuous glucose monitoring systems for diabetic patients. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to provide integration with insulin pumps from Insulet and Tandem for automatic insulin delivery.